Follow-The-Filings

Security · featured owners

VIR Vir Biotechnology Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 0.9%
  • $5M
  • 1 reduce 1 exit

VIR (Vir Biotechnology Inc.) is held in 1 featured 13F book as of 2026 Q2. David Witzke - Avidity Partners Management is the largest tracked holder by portfolio weight (0.85%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 0.9% (David Witzke - Avidity Partners Management) · not free-float ownership

  1. David Witzke Reduce 0.85%

Holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

History
David Witzke - Avidity Partners Management 2026 Q2 0.85% Reduce −45.3% 519,300 $5M History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 22,000 $197K History

1 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 13 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02 Filing Doc
8-K 5.02 Filing Doc
8-K 5.02,5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
8-K 5.02 Filing Doc
8-K 8.01 Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 13 rows shown

Filed Form Detail Links
4 Period Aug 11, 2026 Filing Doc
4 Period Jun 9, 2026 Filing Doc
4 Period Jun 1, 2026 · 2 forms Filing Doc
4 Period May 27, 2026 · 6 forms Filing Doc
4 Period May 1, 2026 Filing Doc
4 Period Apr 29, 2026 Filing Doc
4 Period Apr 6, 2026 Filing Doc
4 Period Apr 1, 2026 Filing Doc
4 Period Mar 23, 2026 Filing Doc
4 Period Mar 20, 2026 Filing Doc
4 Period Mar 2, 2026 Filing Doc
4 Period Feb 24, 2026 · 6 forms Filing Doc
4 Period Feb 22, 2026 · 2 forms Filing Doc

Updated 19 days ago Source: SEC EDGAR submissions All on EDGAR

Financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $74.2M $68.56M
Gross profit * — $73.36M $68.53M
Gross margin * — 98.9% 100.0%
Net income -$615.12M -$521.96M -$437.99M
Net margin * — -703.4% -638.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.59B $1.04B $0.514B
Total non-current assets * $330.83M $356.36M $488.74M
Total assets $1.92B $1.4B $1B
Total current liabilities $175.41M $119.66M $92.82M
Total non-current liabilities * $153.42M $128.77M $144.73M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$778.78M -$446.35M -$391.78M
Cash from investing $164.63M $499.37M $310.37M
Cash from financing $7.48M $4.39M $3.78M
Net change in cash -$606.68M $57.4M -$77.62M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders